Filter
71
Text search:
sinopharm
Featured
Recommendations
8
New Publications
1
Language
Document type
Guidelines
25
Studies & Reports
18
Manuals
9
Fact sheets
8
Situation Updates
5
Strategic & Response Plan
3
Resource Platforms
2
No document type
1
Countries / Regions
Argentina
10
Brazil
6
Paraguay
4
Mozambique
3
Ukraine
3
Nigeria
2
Germany
2
Syria
2
Colombia
2
Chile
2
East and Southern Africa
2
West and Central Africa
2
Latin America and the Carribbean
2
Senegal
1
Guinea-Bissau
1
Ethiopia
1
Zimbabwe
1
Kenya
1
Rwanda
1
Namibia
1
Ecuador
1
El Salvador
1
Angola
1
Middle East and North Africa
1
South–East Asia Region
1
Africa
1
Congo-Brazzaville
1
Authors & Publishers
Publication Years
Category
Countries
45
Clinical Guidelines
2
Pharmacy & Technologies
1
Toolboxes
COVID-19
61
Conflict
3
Refugee
2
AMR
1
Pharmacy
1
Vaccinator's Manual SINOPHARM Vaccine - 28 FEBRUARY 2021
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the COVID-19 Vaccine BIBP/
...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the back
...
O SAGE aplica os princípios da medicina baseada em evidências e estabeleceu um processo metodológico completo para emitir ou atualizar recomendações. Especificamente para vacinas contra a COVID-19, uma descrição detalhada dos processos metodológicos pode ser encontrada no esquema de evidênc
...
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment
...
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition
...
En Paraguay, la vacunación contra COVID-19 inició el 22 de febrero de 2021. Se han autorizado un total de siete vacunas: Bharat-Covaxin, Moderna, Pfizer-BioNTech, AstraZeneca, Sinopharm, Sputnik V- Gamaleya y CoronaVac-Sinovac. Los grupos priorita
...
24 September 2021. The vaccine has been authorized by the Chinese National Regulatory Authority (NRA) – the National Medicinal Product Administration (NMPA) – as well as other regulatory authorities. Because WHO has granted Emergency Use Listing (EUL) for the Sinovac COVID-19 vaccine (Vero Cell
...
African Union and the Africa Centers for Disease Control and Prevention’s Africa Regulatory Taskforce has endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine
10 March 2021
Guidelines for the Vaccination Scheme against
COVID 19: Booster Dose Health Personnel
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
Will COVID-19 vaccines be safe? Will all the COVID-19 candidate vaccines be successful? What are the different phases a vaccine must go through to be approved? This document provides responses to the most frequently asked questions about candidate vaccines and access to COVID-19 vaccination.
This report describes findings from a telephone survey with 1,284 people conducted in February 2021. The survey examined how people respond to public health and social measures (PHSMs) to prevent COVID-19. The sample is representative of households with access to a landline or cell phone, but does n
...
